Trial Profile

Irinotecan Plus Raltitrexed as Second-line Treatment in Advanced Colorectal Cancer Patients: An Open-label, Single-arm, Multicenter Phase II Study

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 20 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irinotecan (Primary) ; Raltitrexed
Indications Colorectal cancer
Focus Therapeutic Use

Most Recent Events

02 Sep 2024 Results(at data cut-off on March 2023, n=108) of combination of raltitrexed and irinotecan as second-line treatment for mCRC , published in the BMC Cancer
04 Jun 2019 Safety and efficacy results published in conjunction with 55th Annual Meeting of the American Society of Clinical Oncology (2019).
17 Feb 2017 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com